首页> 外文期刊>Transactions of the American Ophthalmological Society. >THE IMPORTANCE OF EYELID CLOSURE AND NASOLACRIMAL OCCLUSION FOLLOWING THE OCULAR INSTILLATION OF TOPICAL GLAUCOMA MEDICATIONS, AND THE NEED FOR THE UNIVERSAL INCLUSION OF ONE OF THESE TECHNIQUES IN ALL PATIENT TREATMENTS AND CLINICAL STUDIES
【24h】

THE IMPORTANCE OF EYELID CLOSURE AND NASOLACRIMAL OCCLUSION FOLLOWING THE OCULAR INSTILLATION OF TOPICAL GLAUCOMA MEDICATIONS, AND THE NEED FOR THE UNIVERSAL INCLUSION OF ONE OF THESE TECHNIQUES IN ALL PATIENT TREATMENTS AND CLINICAL STUDIES

机译:眼部植入青光眼药物后眼闭塞和鼻睫状闭塞的重要性,以及在所有患者治疗和临床研究中普遍采用其中一种技术的需求

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: To review the effects of nasolacrimal occlusion (NLO) and eyelid closure (ELC) on the ocular and systemic absorption of topically applied glaucoma medications and emphasize the need for the universal application of these techniques during patient treatment and in clinical studies of topically applied glaucoma medications. Methods: Following a review of data suggesting great clinical benefit from NLO and ELC, the absence of inclusion of these simple techniques in published studies of topical glaucoma medications is identified. The effect of this oversight on these studies is noted with reference to each of the 5 major groups of glaucoma medications. Results: A review of the literature suggests that NLO and ELC improve intraocular penetration of topically applied glaucoma medications and discourage systemic absorption. The US Food and Drug Administration and the National Institutes of Health discourage the inclusion of these techniques in studies of the efficacy and toxicity of topically applied glaucoma medications. Consequently, all glaucoma studies reported in the literature lack the inclusion of these techniques for 5 minutes. This omission has major implications for patient informed consent, study protocol consistency, and the value of clinical studies, and directly affects the therapeutic index of glaucoma medications in unpredictable and undesirable ways. The undesirable influence on the therapeutic index of each drug influences the safety and efficacy and has implications for the cost of medical treatments, the reproducibility of clinical study results, and dosing regimens, including those of combination therapy, as reflected in the peer-reviewed literature. Conclusions: Patients should use NLO or ELC for 5 minutes following eye drop treatment with topically applied glaucoma medications. Furthermore, it is essential that these techniques be included in all clinical studies of topically applied glaucoma medications to ensure the most favorable therapeutic index and its accurate determination. This will also help provide the most consistent, reliable, and reproducible study results.
机译:目的:回顾鼻泪闭塞(NLO)和眼睑闭合(ELC)对局部应用青光眼药物的眼部和全身吸收的影响,并强调在患者治疗期间和局部应用的临床研究中必须普遍使用这些技术青光眼药物。方法:对表明NLO和ELC具有巨大临床益处的数据进行审查后,发现在局部青光眼药物的已发表研究中没有包括这些简单的技术。参照5个主要的青光眼药物组,注意到了这些研究的监督效果。结果:文献综述表明,NLO和ELC可以改善局部应用青光眼药物的眼内渗透率,并阻碍全身吸收。美国食品和药物管理局和美国国立卫生研究院不鼓励在局部应用青光眼药物的功效和毒性研究中使用这些技术。因此,文献中报道的所有青光眼研究在5分钟内都没有包括这些技术。这种遗漏对患者的知情同意,研究方案的一致性以及临床研究的价值具有重大意义,并且以不可预测和不期望的方式直接影响青光眼药物的治疗指数。对每种药物的治疗指数的不良影响会影响安全性和疗效,并会影响药物治疗的成本,临床研究结果的可重复性以及包括联合治疗在内的给药方案,这在同行评审的文献中都有反映。 。结论:在局部应用青光眼药物进行眼药水治疗后,患者应使用NLO或E​​LC 5分钟。此外,必须将这些技术包括在局部应用青光眼药物的所有临床研究中,以确保最有利的治疗指数及其准确测定。这也将有助于提供最一致,最可靠和可重复的研究结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号